The potential of using artificial intelligence in drug discovery and development has sparked both excitement and ...
Mural nominated two new development candidates, MURA-8518 a novel binding protein-resistant IL-18 with half-life extension, ...
Eliem Therapeutics is continuing its transformation into an immune-mediated disease company by paying $9 million to ...
Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), a clinical-stage biotechnology company pioneering innovative cancer and viral infection ...
Alpha Cognition and China Medical System sign a $44M licensing deal for Zunveyl. ALPHA-1062 preclinical data shows benefits ...
News Medical on MSN6d
Insilico Medicine nominates ISM1745 as preclinical candidate for MTAP-deleted cancersInsilico Medicine ('Insilico'), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announced the nomination of ISM1745, a potentially best-in ...
WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology ...
(NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in collaboration with AstralBio Inc., announced today the development of an antibody that inhibits the function of Activin ...
ISM5411 was well tolerated and demonstrated a favourable pharmokinetic profile in validating gut-restrictive properties.
A Look Back at an Exciting 2024 LONDON, UNITED KINGDOM / ACCESSWIRE / January 6, 2025 / 2024 has been an incredible year for Genflow as we advance our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback